Evidence map›Paper›PMID 22315274›Full record

GuidelineChest2012

Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Per Olav Vandvik, A Michael Lincoff, Joel M Gore, David D Gutterman, Frank A Sonnenberg, Pablo Alonso-Coello, Elie A Akl, Maarten G Lansberg, Gordon H Guyatt, Frederick A Spencer

Erratum issued Registry-linked trialAbstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Chest, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02513004 (Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel in Patients Undergoing "One-stop" Hybrid Coronary Revascularization), which is not on this map. Cited by 160 papers, 15 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
160citing papers in PubMed, 15 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02513004 phase4unknown statusnot on this mapstarted 2015, after this paper: background citation

Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel in Patients Undergoing "One-stop" Hybrid Coronary Revascularization

TypeinterventionalSponsorYongjian WuRan2015 to 2017Enrolled60ConditionsCoronary DiseaseArmsTicagrelor, Clopidogrel
3 · Its place in the literature

Who cites it

160 citing papers in PubMed, 15 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Canadian Stroke Best Practice Recommendations, seventh edition: acetylsalicylic acid for prevention of vascular events.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2020
    Guideline
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2017
    Guideline
  8. Pooled it
  9. Pooled it
  10. A systematic review of aspirin in primary prevention: is it time for a new approach?American journal of cardiovascular drugs : drugs, devices, and other interventions · 2015
    Pooled it
  11. Pooled it
  12. Pooled it
  13. Guideline
  14. Guideline
  15. Guideline
  16. Trial
  17. Trial
  18. Trial
  19. Article
  20. Article

100 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
    Dosage error in article text
5 · Who and what money

Authors and funding

10 authors.

Per Olav VandvikNorwegian Knowledge Centre for the Health Services and Department of Medicine, Innlandet Hospital Trust Gjøvik, Gjøvik, Norway.
A Michael LincoffDepartment of Cardiovascular Medicine and Cleveland Clinic Coordinating Center for Clinical Research (C5Research), Cleveland Clinic, Cleveland, OH.
Joel M GoreDepartment of Medicine, University of Massachusetts Medical School, Worcester, MA.
David D GuttermanDepartment of Medicine, Medical College of Wisconsin, Milwaukee, WI.
Frank A SonnenbergDepartment of Medicine, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ.
Pablo Alonso-CoelloIberoamerican Cochrane Centre, CIBERESP-IIB Sant Pau, Barcelona, Spain.
Elie A AklDepartment of Medicine and Department of Clinical Epidemiology and Biostatistics, State University of New York at Buffalo, Buffalo, NY.
Maarten G LansbergStanford Stroke Center, Stanford University Medical Center, Palo Alto, CA.
Gordon H GuyattDepartment of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada; Department of Medicine, McMaster University, Hamilton, ON, Canada.
Frederick A SpencerDepartment of Medicine, McMaster University, Hamilton, ON, Canada. Electronic address: fspence@mcmaster.ca.

Funding

Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-Based ClinicalR13HL104758 · NHLBI · AMERICAN COLLEGE OF CHEST PHYSICIANS · PI LEWIS, SANDRA ZELMAN · 2010 to 2010
$11k
NHLBI NIH HHS R13 HL104758
6 · The paper itself

Abstract

backgroundThis guideline focuses on long-term administration of antithrombotic drugs designed for primary and secondary prevention of cardiovascular disease, including two new antiplatelet therapies.

methodsThe methods of this guideline follow those described in Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines in this supplement.

resultsWe present 23 recommendations for pertinent clinical questions. For primary prevention of cardiovascular disease, we suggest low-dose aspirin (75-100 mg/d) in patients aged > 50 years over no aspirin therapy (Grade 2B). For patients with established coronary artery disease, defined as patients 1-year post-acute coronary syndrome, with prior revascularization, coronary stenoses > 50% by coronary angiogram, and/or evidence for cardiac ischemia on diagnostic testing, we recommend long-term low-dose aspirin or clopidogrel (75 mg/d) (Grade 1A). For patients with acute coronary syndromes who undergo percutaneous coronary intervention (PCI) with stent placement, we recommend for the first year dual antiplatelet therapy with low-dose aspirin in combination with ticagrelor 90 mg bid, clopidogrel 75 mg/d, or prasugrel 10 mg/d over single antiplatelet therapy (Grade 1B). For patients undergoing elective PCI with stent placement, we recommend aspirin (75-325 mg/d) and clopidogrel for a minimum duration of 1 month (bare-metal stents) or 3 to 6 months (drug-eluting stents) (Grade 1A). We suggest continuing low-dose aspirin plus clopidogrel for 12 months for all stents (Grade 2C). Thereafter, we recommend single antiplatelet therapy over continuation of dual antiplatelet therapy (Grade 1B).

conclusionsRecommendations continue to favor single antiplatelet therapy for patients with established coronary artery disease. For patients with acute coronary syndromes or undergoing elective PCI with stent placement, dual antiplatelet therapy for up to 1 year is warranted.

Indexed as

Evidence-Based MedicineSocieties, MedicalAgedAngioplasty, Balloon, CoronaryCardiovascular DiseasesCombined Modality TherapyCoronary DiseaseDose-Response Relationship, DrugDrug Therapy, CombinationFibrinolytic AgentsHumansLong-Term CareMiddle AgedMyocardial IschemiaPlatelet Aggregation InhibitorsRisk FactorsFibrinolytic AgentsPlatelet Aggregation Inhibitors

Identifiers

PMID22315274
PMCPMC3278064

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.